デフォルト表紙
市場調査レポート
商品コード
1492237

アトピー性皮膚炎市場:薬剤クラス別、投与経路別、流通チャネル別-世界予測2024-2030年

Atopic Dermatitis Market by Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids), Route of Administration (Injectable, Oral, Topical), Distribution Channel - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
アトピー性皮膚炎市場:薬剤クラス別、投与経路別、流通チャネル別-世界予測2024-2030年
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アトピー性皮膚炎市場規模は2023年に63億8,000万米ドルと推計され、2024年には67億4,000万米ドルに達し、CAGR 5.88%で2030年には95億3,000万米ドルに達すると予測されています。

一般に湿疹として知られるアトピー性皮膚炎は、皮膚の乾燥、かゆみ、炎症を引き起こす慢性の皮膚疾患です。多くの場合、幼児期に発症し、成人期まで持続することもあれば、時間の経過とともに治癒することもあります。アトピー性皮膚炎を持つ個人の皮膚は、しばしばバリア機能が低下した徴候を示し、感染症や刺激に弱くなります。この病態の管理には、保湿、誘因の回避、処方された薬剤による症状および炎症のコントロールが一般的です。アトピー性皮膚炎のニーズは、乾燥肌、ひどいかゆみ、炎症性発疹を特徴とする症状の世界の有病率の増加とともに、著しく増加しています。また、先進国、新興国を問わず、国民の意識の高まりやヘルスケア支出の増大も市場拡大の大きな要因となっています。さらに、政府や医療機関の取り組みは、治療へのアクセスや購入しやすさを向上させる上で極めて重要です。しかし、先進的治療に伴う高額な費用が多くの患者のアクセスを制限する可能性があるなど、市場は課題に直面しています。また、地域によって異なる規制環境の複雑さも、製品の入手を妨げ、開発コストを膨れ上がらせる可能性があります。このような問題があるにもかかわらず、遠隔医療の導入は、特に遠隔患者管理のための重要な機会として浮上しており、それによってアトピー性皮膚炎治療を含むヘルスケア・サービスへのアクセシビリティが向上しています。さらに、個別化医療へのシフトは治療効果の向上を示し、この分野の患者ケアに革命をもたらす可能性があります。

主な市場の統計
基準年[2023] 63億8,000万米ドル
予測年[2024] 67億4,000万米ドル
予測年 [2030] 95億3,000万米ドル
CAGR(%) 5.88%

地域別の洞察

アトピー性皮膚炎治療の地域情勢は、ヘルスケアインフラ、患者の認知度、経済の多様性などの多様な要因の影響を受け、世界各地域で顕著なばらつきが見られます。南北アメリカでは、アトピー性皮膚炎に対する高い認識と確立されたヘルスケアの枠組みが、先進的な治療オプションの採用と継続的な医薬品の研究開発を支え、革新的な製剤や生物製剤を通じて患者の転帰を向上させています。欧州も同様の成長パターンを示しており、その強固なヘルスケア政策と、規制当局の承認を合理化するイニシアチブによって促進される最先端研究への重点的な取り組みによって、同様の成長パターンを示しています。中東とアフリカはヘルスケアの能力と意識が向上しており、アトピー性皮膚炎治療市場に新たな成長の可能性をもたらしています。アジア太平洋地域は、ヘルスケアへの投資が急増し、伝統的な治療法と近代的な医療行為の融合という独自の傾向を持つ、ダイナミックで急速に発展する市場です。先進的なヘルスケアシステムを持つ日本とオーストラリアは、皮膚科学の強力な研究部門に支えられ、治療導入の革新を続けています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、アトピー性皮膚炎市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、ビジネス戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。

市場シェア分析

市場シェア分析は、アトピー性皮膚炎市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、アトピー性皮膚炎市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • アトピー性皮膚炎の発生率増加
      • 食物アレルギーの増加が深刻化アトピー性皮膚炎
      • 皮膚バリア保護効果のある新規保湿剤、生物製剤、脂質補給外用薬の開発
    • 抑制要因
      • 治療費の高騰
    • 機会
      • 病気の治療法の入手可能性に関する意識の高まり
      • さまざまな新興諸国で治療へのアクセスが拡大
    • 課題
      • 薬の使用に伴う副作用
  • 市場セグメンテーション分析
    • 薬物クラス:より高い有効性と最小限の副作用を持つ阻害剤の大きな利点
    • 流通チャネル:宅配サービスや割引によりオンライン薬局の好感度が高まっている
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 アトピー性皮膚炎市場薬剤クラス別

  • 生物学的製剤
  • カルシニューリン阻害剤
  • コルチコステロイド
  • PDE-4阻害剤

第7章 アトピー性皮膚炎市場:投与経路別

  • 注射可能
  • オーラル
  • 話題

第8章 アトピー性皮膚炎市場:流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 南北アメリカのアトピー性皮膚炎市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のアトピー性皮膚炎市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのアトピー性皮膚炎市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • ジョンソン・エンド・ジョンソン、プロテオロジックスを戦略的に買収し、アトピー性皮膚炎と喘息治療の選択肢を強化
    • イーライリリーのレブリキズマブがアトピー性皮膚炎の有色人種の皮膚に有効性を実証
    • グレンマークとファイザーがインドで新たなアトピー性皮膚炎治療を導入
  • 戦略分析と提言

第13章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. ATOPIC DERMATITIS MARKET RESEARCH PROCESS
  • FIGURE 2. ATOPIC DERMATITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ATOPIC DERMATITIS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ATOPIC DERMATITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PDE-4 INHIBITOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PDE-4 INHIBITOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 287. ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 288. ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-FE70EC183B6D

[186 Pages Report] The Atopic Dermatitis Market size was estimated at USD 6.38 billion in 2023 and expected to reach USD 6.74 billion in 2024, at a CAGR 5.88% to reach USD 9.53 billion by 2030.

Atopic dermatitis, commonly known as eczema, is a chronic skin condition causing dry, itchy, and inflamed skin. It often starts in the early childhood and can persist into adulthood or resolve over time. The individual's skin with atopic dermatitis often shows signs of a compromised barrier, making it more susceptible to infections and irritants. Management of the condition typically involves moisturizing regimens, avoiding triggers, and using prescribed medications to control symptoms and inflammation. The need for atopic dermatitis is experiencing a significant increase, with an increasing global prevalence of the condition characterized by dry skin, severe itching, and inflamed rashes. The rising public awareness and augmented healthcare spending across both developed and developing nations are also considerable factors in the expansion of the market. Moreover, government and health organizations' initiatives are pivotal in enhancing treatment accessibility and affordability. However, the market faces challenges, such as the high costs associated with advanced treatments, which may restrict access for many patients. The complexity of regulatory environments across different regions can also hinder product availability and inflate development costs. Despite these issues, the incorporation of telemedicine has emerged as a key opportunity, particularly for remote patient management, thereby increasing the accessibility of healthcare services, including atopic dermatitis treatment. Additionally, the shift towards personalized medicine showcases enhancements in treatment efficacy, which could revolutionize patient care in this field.

KEY MARKET STATISTICS
Base Year [2023] USD 6.38 billion
Estimated Year [2024] USD 6.74 billion
Forecast Year [2030] USD 9.53 billion
CAGR (%) 5.88%

Regional Insights

The geographical landscape for atopic dermatitis treatment displays pronounced variation across global regions, influenced by diverse factors such as healthcare infrastructure, patient awareness, and economic diversity. In the Americas, high awareness of atopic dermatitis and well-established healthcare frameworks support the adoption of advanced treatment options and ongoing pharmaceutical R&D, enhancing patient outcomes through innovative drug formulations and biologics. Europe displays similar growth patterns with its robust healthcare policies and an emphasis on cutting-edge research facilitated by initiatives that streamline regulatory approvals. The Middle East and Africa are advancing in healthcare capabilities and awareness, which significantly presents new growth avenues for the atopic dermatitis treatment market. The Asia-Pacific region showcases a dynamic and rapidly evolving market, with a surge in healthcare investment and a unique inclination towards integrating traditional remedies with modern medical practices. Japan and Australia, with their advanced healthcare system, continue to innovate treatment adoption, backed by strong research sectors in dermatology.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Atopic Dermatitis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing incidence of atopic dermatitis
      • Growing prevalence of food allergies intensifying atopic dermatitis
      • Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
    • Market Restraints
      • High cost of therapeutics
    • Market Opportunities
      • Rising awareness regarding the availability of treatments for the disease
      • Growing access to treatment in various developing countries
    • Market Challenges
      • Adverse effects associated with the use of medication
  • Market Segmentation Analysis
    • Drug Class: Significant benefits of inhibitors with higher efficacy and minimal side effects
    • Distribution Channel: Growing preferences for online pharmacies owing to home delivery services and discounts
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Atopic Dermatitis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Atopic Dermatitis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Johnson & Johnson's Strategic Acquisition of Proteologix to Enhance Atopic Dermatitis and Asthma Treatment Options

Johnson & Johnson Services, Inc. has announced the acquisition of Proteologix, Inc., a biotechnology company focused on developing bispecific antibodies for immune-mediated diseases. The purchase, valued at USD 850 million in cash, along with potential additional milestone payments, aims to broaden Johnson & Johnson's immunology portfolio. Proteologix boasts pivotal assets, including PX128 and PX130, as well as bispecific antibodies targeting multiple cytokines associated with atopic dermatitis (AD) and asthma. PX128, which is expected to enter phase 1 development, targets both IL-13 and TSLP, central mediators in Th2 skin inflammation and tissue inflammation, respectively. [Published On: 2024-05-16]

Eli Lilly's Lebrikizumab Demonstrates Efficacy in Skin of Color for Atopic Dermatitis

Eli Lilly and Company announced positive results from a pioneering Phase 3 clinical study of lebrikizumab aimed at treating moderate-to-severe atopic dermatitis (AD) in individuals with skin of color. Unveiled at the American Academy of Dermatology Annual Meeting, this research marks a significant stride, focusing on patient demographics often underrepresented in clinical trials. The 16-week study showcased lebrikizumab's substantive efficacy in skin clearance and itch relief among 50 participants, which aligns with prior outcomes observed in broader Phase 3 trials, thus potentially positioning lebrikizumab as a leading biologic treatment post topical therapies across diverse skin tones. [Published On: 2024-03-10]

Glenmark and Pfizer Introduce New Atopic Dermatitis Treatment in India

Glenmark Pharmaceuticals Limited, in collaboration with Pfizer Inc., has launched a novel treatment for atopic dermatitis in India named Abrocitinib. This innovative oral medication is specifically designed to offer relief to patients suffering from moderate-to-severe forms of the condition. Abrocitinib's introduction into the Indian market represents a significant advancement, addressing the unmet needs of numerous patients whose daily lives are impacted by this chronic skin disease. [Published On: 2024-01-31]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Atopic Dermatitis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma S.A., GlaxoSmithKline PLC, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Atopic Dermatitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Biologics
    • Calcineurin Inhibitors
    • Corticosteroids
    • PDE-4 Inhibitor
  • Route of Administration
    • Injectable
    • Oral
    • Topical
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of atopic dermatitis
      • 5.1.1.2. Growing prevalence of food allergies intensifying atopic dermatitis
      • 5.1.1.3. Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising awareness regarding the availability of treatments for the disease
      • 5.1.3.2. Growing access to treatment in various developing countries
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with the use of medication
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Significant benefits of inhibitors with higher efficacy and minimal side effects
    • 5.2.2. Distribution Channel: Growing preferences for online pharmacies owing to home delivery services and discounts
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Atopic Dermatitis Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Calcineurin Inhibitors
  • 6.4. Corticosteroids
  • 6.5. PDE-4 Inhibitor

7. Atopic Dermatitis Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Topical

8. Atopic Dermatitis Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Atopic Dermatitis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Atopic Dermatitis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Atopic Dermatitis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Johnson & Johnson's Strategic Acquisition of Proteologix to Enhance Atopic Dermatitis and Asthma Treatment Options
    • 12.3.2. Eli Lilly's Lebrikizumab Demonstrates Efficacy in Skin of Color for Atopic Dermatitis
    • 12.3.3. Glenmark and Pfizer Introduce New Atopic Dermatitis Treatment in India
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio